# An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

> **NCT04240639** · NA · UNKNOWN · sponsor: **Nanospectra Biosciences, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasms of the Prostate

## Interventions

- **DEVICE:** AuroShell particle infusion

## Key facts

- **NCT ID:** NCT04240639
- **Lead sponsor:** Nanospectra Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04240639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04240639, "An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT04240639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*